(Total Views: 416)
Posted On: 01/31/2020 6:50:42 AM
Post# of 153974
The did quickly mention a third at the end, but exact results on patient 2, maybe a typo.. not sure. Either way, great new results!
New data from the first patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of circulating tumor cells (CTC) with leronlimab in combination with carboplatin at 16 weeks of treatment. In addition, this patient experienced significant reductions in epithelial-mesenchymal transition (EMT) cells dropping to zero after five weeks with treatment and currently reports zero EMT. New data from the second patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of CTC with leronlimab in combination with carboplatin after two weeks of treatment. This patient also showed a 70% reduction in EMT cells after just two weeks of treatment. Initial data from the third patient in the mTNBC trial indicated the CTC dropped to zero after two weeks of treatment with leronlimab.
New data from the first patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of circulating tumor cells (CTC) with leronlimab in combination with carboplatin at 16 weeks of treatment. In addition, this patient experienced significant reductions in epithelial-mesenchymal transition (EMT) cells dropping to zero after five weeks with treatment and currently reports zero EMT. New data from the second patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of CTC with leronlimab in combination with carboplatin after two weeks of treatment. This patient also showed a 70% reduction in EMT cells after just two weeks of treatment. Initial data from the third patient in the mTNBC trial indicated the CTC dropped to zero after two weeks of treatment with leronlimab.
(1)
(0)
